Need professional-grade analysis? Visit stockanalysis.com
$10.61B
25.42
40,132
1.55%
Price Chart
Risk-Adjusted Performance
Laobaixing Pharmacy (603883) Price Performance
Laobaixing Pharmacy (603883) trades on SHG in CNY. The company is classified in the Healthcare sector under the Pharmaceutical Retailers industry. The stock currently trades at CNY13.68, down 4.40% from the previous close.
Over the past year, 603883 has traded between a low of CNY13.68 and a high of CNY22.52. The stock has lost 28.4% over this period. It is currently 39.3% below its 52-week high.
Laobaixing Pharmacy has a market capitalization of $10.61B, with a price-to-earnings ratio of 25.42 and a dividend yield of 1.55%.
About Laobaixing Pharmacy
LBX Pharmacy Chain Joint Stock Company operates a chain of pharmacy stores in Mainland China. The company operates through three segments: Retail business, Wholesale business, and Other. It engages in commodity retail and wholesale business; and pharmaceutical manufacturing business and others, as well as sells drugs, and other health and beauty-related products through its marketing network. The company is also involved in wholesale and retail of pharmaceutical products; Chinese medicine research and development; E-commerce; food and department store retail; commodity wholesale; and retail of maternal and infant products. In addition, it provides business, information technology consulting, technical, pharmaceutical consulting, clinic, and medical services. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is headquartered in Changsha, China.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Exchange
- SHG
- Currency
- CNY
- Country
- China
Financial Metrics
- Revenue (TTM)
- $22.20B
- EBITDA
- $1.10B
- Profit Margin
- 1.88%
- EPS (TTM)
- 0.55
- Book Value
- 8.95
Technical Indicators
- 52 Week High
- CN¥22.97
- 52 Week Low
- CN¥13.65
- 50 Day MA
- CN¥15.07
- 200 Day MA
- CN¥16.95
- Beta
- 0.66
Valuation
- Trailing P/E
- 25.42
- Forward P/E
- N/A
- Price/Sales
- 0.48
- Price/Book
- 1.59
- Enterprise Value
- $13.67B